Get the Stockscreener App
12.45
14.14%
-2.05
Pre-market:
12.39
-0.06
-0.48%
Zenas Biopharma Inc stock is traded at $12.45, with a volume of 418.91K.
It is down -14.14% in the last 24 hours and down -41.66% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$14.50
Open:
$14.42
24h Volume:
418.91K
Relative Volume:
3.89
Market Cap:
$520.30M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-34.82%
1M Performance:
-41.66%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.65
$14.61
1-Week Range:
$11.65
$20.50
52-Week Range:
$11.65
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
1000 WINTER ST, SUITE 1200, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ZBIO | 12.45 | 520.30M | 0 | 0 | 0 | 0.00 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 - Investing.com
FMR LLC Acquires New Stake in Zenas BioPharma Inc - GuruFocus.com
Zenas BioPharma Inc. (ZBIO) Quarterly 10-Q Report - Quartzy
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Raises $259M in IPO, Advances Phase 3 Trial Amid Growing R&D Investment | ZBIO Stock News - StockTitan
Zenas BioPharma Completes Targeted Enrollment of the Phase - GlobeNewswire
Zenas BioPharma Hits Milestone: Completes Enrollment in Largest-Ever IgG4-RD Trial | ZBIO Stock News - StockTitan
Zenas BioPharma To Attend Upcoming Healthcare Investor Conferences - BERNAMA
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences - BERNAMA
TSX Global Base Metals EW Index (TXBE) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Arm Holdings Plc ADR (ARM-Q) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Zenas BioPharma (ZBIO) to Present at 4 Major Healthcare Investor Conferences | ZBIO Stock News - StockTitan
Zenas Bio: Recent IPO With Late-Stage Candidate (NASDAQ:ZBIO) - Seeking Alpha
Zenas started at buy by four banks on lead drug potential (NASDAQ:ZBIO) - Seeking Alpha
Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab - Investing.com Canada
Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum - Investing.com Canada
Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials - Investing.com Canada
Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials - Investing.com Canada
Biopharma financings surge to $86.2B in 2024, with $8.7B in September - BioWorld Online
Halda appoints new chief executive - The Pharma Letter
IgG4-related Disease Market to Show Remarkable Growth Trends - openPR
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com India
Zenas BioPharma CEO acquires $360k worth of company shares By Investing.com - Investing.com South Africa
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - The Korea Bizwire
Zenas BioPharma’s $225 Million IPO - Global Legal Chronicle
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase ... - The Bakersfield Californian
Zenas BioPharma Announces Closing of Full Exercise of - GlobeNewswire
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in - EIN News
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Waltham biotech joins IPO buzz, plans to list on Nasdaq - The Business Journals
Zenas BioPharma sees $15 million in stock purchases by Zebra Aggregator - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock - Investing.com Canada
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
Zenas BioPharma director buys $7.48m in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director buys $7.48m in company stock - Investing.com
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock - Investing.com India
Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock - Investing.com India
SR One Capital management buys $38m of Zenas BioPharma stock - Investing.com Australia
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
| ENRIGHT PATRICK G | Director |
Sep 16 '24 |
Buy |
17.00 |
440,000 |
7,480,000 |
774,530 |
| Nunn Jason Raleigh | Director |
Sep 16 '24 |
Buy |
17.00 |
882,352 |
14,999,984 |
1,946,564 |
| Fairmount Funds Management LLC | Director |
Sep 16 '24 |
Buy |
17.00 |
300,000 |
5,100,000 |
1,604,891 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
2,235,294 |
37,999,998 |
1,946,564 |
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):